0.5252
9.46%
-0.0549
After Hours:
.50
-0.0252
-4.80%
Silexion Therapeutics Corp stock is traded at $0.5252, with a volume of 380.98K.
It is down -9.46% in the last 24 hours and down -64.03% over the past month.
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
See More
Previous Close:
$0.5801
Open:
$0.5745
24h Volume:
380.98K
Relative Volume:
0.33
Market Cap:
$5.38M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-31.81%
1M Performance:
-64.03%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
2 HAMAYAN STREET, MODIIN-MACCABIM-REUT
Silexion Therapeutics Corp Stock (SLXN) Latest News
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise - MSN
A new trading data show Silexion Therapeutics Corp (SLXN) is showing positive returns. - SETE News
In the Green: Silexion Therapeutics Corp (SLXN) Closes at 0.64, Up/Down -16.28 from Previous Day - The Dwinnex
SLXN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year - Benzinga
Diabetic Kidney Disease Market Revenue to Expand Significantly - openPR
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment - openPR
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise - Benzinga
Silexion reports improved outcomes in pancreatic cancer trial - Investing.com
Silexion reports improved outcomes in pancreatic cancer trial - Investing.com India
Silexion Therapeutics announces new findings from Loder trial - TipRanks
Stanrose Mafatlal Investments and Finance Limited (STANROS.BO) Latest Stock News & Headlines - Yahoo Finance
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer - Business Wire
Silexion Therapeutics sees board member resignation - Investing.com
Silexion Therapeutics Corp Announces Resignation of Ilan Shiloah as Independent Director, Member of Audit Committee, the Compensation Committee, and the Corporate Governance and Nominating Committee - Marketscreener.com
Emerging Precision Oncology Companies Show Promise Following Summit’s Success - Vancity Buzz
Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR
Industry Update: 3 Exciting Precision Oncology Players to Watch - WICZ
'We've run out of money' says bar owner as venue closes after nine months - Liverpool Echo
Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - Defense World
Australia's Sims tops benchmark gains on positive FY25 start - XM
The Potential Rise in the Price of Symbotic Inc (SYM) following insiders activity - Knox Daily
Symbotic (NASDAQ:SYM) Stock Price Up 4.9% - Defense World
Supply@ME Capital (LON:SYME) Sets New 1-Year Low at $0.01 - Defense World
SEGULA Technologies inaugurates new USA headquarters and a Technicon Design studio in Troy, Michigan - WV News
Symbotic (NASDAQ:SYM) Trading Up 1.2% - Defense World
Investor’s Delight: E.W. Scripps Co. (SSP) Closes Strong at 1.95, Up 2.63 - The Dwinnex
Is Spyre Therapeutics Inc. (SYRE) positioned for future growth? - SETE News
Does E.W. Scripps Co. (SSP) offer a good opportunity for investors? - SETE News
Symphera Raises €2.4M in Seed Financing - FinSMEs
Silvis Materials Awarded $1 Million NSF SBIR Phase II Grant to Reduce Emissions in Packaging and Building - EIN News
Stock Traders Buy High Volume of Put Options on Symbotic (NASDAQ:SYM) - Defense World
‘He was brilliant’: Shwab Elementary teachers remember student killed in accidental shooting Saturday night - WSMV 4
Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - MarketBeat
Do investors need to be concerned about Spyre Therapeutics Inc. (SYRE)? - US Post News
E.W. Scripps Co. (SSP) did well last session? - US Post News
Régis Le Bris explains Sunderland's Jewison Bennette plan after loan disappointment and position switch - Sunderland Echo
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5% - MarketBeat
Daily Market Movement: Spyre Therapeutics Inc. (SYRE) Sees a 3.23 Increase, Closing at 29.36 - The Dwinnex
Synectics says trading is 'significantly ahead' of previous guidance - Proactive Investors USA
Vertical Research slashes price target on Symbotic Inc [SYM] – find out why. - The DBT News
Research reports, insider buys and stellar earnings have these stocks firing - RagingBull
SLXN: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Market Momentum: Silexion Therapeutics Corp (SLXN) Registers a 11.61 Increase, Closing at 0.98 - The Dwinnex
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers - StockTitan
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers - Yahoo Finance
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference - GlobeNewswire
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference - Yahoo Finance
SLXN’s Debt-to-Equity Ratio at 1.32: What It Means for Silexion Therapeutics Corp’s Future - The InvestChronicle
Silexion Therapeutics Corp Stock (SLXN) Financials Data
There is no financial data for Silexion Therapeutics Corp (SLXN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):